MX2011009568A - Inhibidores de la rho cinasa. - Google Patents
Inhibidores de la rho cinasa.Info
- Publication number
- MX2011009568A MX2011009568A MX2011009568A MX2011009568A MX2011009568A MX 2011009568 A MX2011009568 A MX 2011009568A MX 2011009568 A MX2011009568 A MX 2011009568A MX 2011009568 A MX2011009568 A MX 2011009568A MX 2011009568 A MX2011009568 A MX 2011009568A
- Authority
- MX
- Mexico
- Prior art keywords
- rock2
- kinase inhibitors
- rho kinase
- rock1
- inhibitors
- Prior art date
Links
- 239000003590 rho kinase inhibitor Substances 0.000 title 1
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 abstract 4
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 abstract 4
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 abstract 3
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a inhibidores de ROCK1 y ROCK2 que pueden ser selectivos para ROCK2 y a métodos para modular las propiedades farmacocinéticas y/o farmacodinámicas de dichos compuestos. También se proporcionan métodos para inhibir ROCK1 y/o ROCK2. También se proporcionan tratamientos que combinan inhibidores de ROCK1 y/o ROCK2 con estatinas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15870509P | 2009-03-09 | 2009-03-09 | |
| PCT/US2010/026656 WO2010104851A1 (en) | 2009-03-09 | 2010-03-09 | Rho kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011009568A true MX2011009568A (es) | 2011-12-06 |
Family
ID=42728706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009568A MX2011009568A (es) | 2009-03-09 | 2010-03-09 | Inhibidores de la rho cinasa. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120202793A1 (es) |
| EP (1) | EP2406236A4 (es) |
| JP (1) | JP2012519732A (es) |
| AU (1) | AU2010222848A1 (es) |
| CA (1) | CA2755095A1 (es) |
| MX (1) | MX2011009568A (es) |
| WO (1) | WO2010104851A1 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105007939B (zh) * | 2012-10-05 | 2018-10-19 | 卡德门企业有限公司 | 人抗vegfr-2/kdr抗体 |
| US9765039B2 (en) * | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US20150297679A1 (en) * | 2012-12-14 | 2015-10-22 | The Brigham And Women's Hospital, Inc. | Methods and assays relating to macrophage differentiation |
| CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
| PL3010503T3 (pl) | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| EP3027604B1 (en) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
| US11311541B2 (en) * | 2014-04-09 | 2022-04-26 | Kadmon Corporation, Llc | Treatment of GVHD |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| CN107207474B (zh) | 2014-12-11 | 2021-05-07 | 恒翼生物医药科技(上海)有限公司 | 被取代的杂环作为溴结构域抑制剂 |
| US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| US11021468B2 (en) * | 2015-04-01 | 2021-06-01 | Rigel Pharmaceuticals, Inc. | TGF-ß inhibitors |
| CA3046997A1 (en) * | 2016-12-13 | 2018-06-21 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
| US11787783B2 (en) | 2016-12-13 | 2023-10-17 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
| CN106916145B (zh) * | 2017-03-06 | 2019-06-04 | 上海应用技术大学 | SLx-2119的合成方法 |
| JP2020525525A (ja) | 2017-06-30 | 2020-08-27 | ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用 |
| WO2019000683A1 (zh) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| ES2969536T3 (es) | 2017-06-30 | 2024-05-21 | Beijing Tide Pharmaceutical Co Ltd | Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso |
| US11548867B2 (en) | 2017-07-19 | 2023-01-10 | Idea Ya Biosciences, Inc. | Amido compounds as AhR modulators |
| CN111406051A (zh) | 2017-09-03 | 2020-07-10 | 安吉昂生物医药公司 | 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙烯基杂环 |
| EP3710008A4 (en) | 2017-11-14 | 2021-08-25 | The Schepens Eye Research Institute, Inc. | RUNX1 INHIBITION FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND DISEASES ASSOCIATED WITH EPITHELIAL-MESENCHYMAL TRANSITION |
| ES2946632T7 (es) | 2018-02-06 | 2025-03-04 | Ideaya Biosciences Inc | Moduladores de AhR |
| JP7187575B2 (ja) | 2018-04-18 | 2022-12-12 | メッドシャイン ディスカバリー インコーポレイテッド | Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物 |
| WO2020047229A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| WO2021073592A1 (zh) | 2019-10-18 | 2021-04-22 | 南京明德新药研发有限公司 | 作为rho激酶抑制剂的苯并吡唑类化合物的盐型、晶型及其制备方法 |
| WO2021129589A1 (zh) * | 2019-12-27 | 2021-07-01 | 广东东阳光药业有限公司 | Kd-025的新晶型及其制备方法 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| EP4155308A4 (en) * | 2020-07-14 | 2024-04-17 | Wuhan LL Science and Technology Development Co., Ltd. | ROCK INHIBITOR AND PRODUCTION PROCESS AND USE THEREOF |
| WO2022017412A1 (zh) * | 2020-07-22 | 2022-01-27 | 北京泰德制药股份有限公司 | 治疗造血干细胞移植后的移植物抗宿主病的方法 |
| CN114105976B (zh) * | 2020-08-28 | 2024-04-26 | 杭州邦顺制药有限公司 | 选择性rock2激酶抑制剂 |
| CN116438175B (zh) * | 2020-11-11 | 2025-07-22 | 南京明德新药研发有限公司 | 苯并脲环衍生物及其制备方法和应用 |
| CN115124514A (zh) * | 2021-03-26 | 2022-09-30 | 广东东阳光药业有限公司 | Kd-025的共晶及其制备方法 |
| EP4431596A1 (en) | 2021-11-11 | 2024-09-18 | The Doshisha | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
| US20250223279A1 (en) * | 2022-03-31 | 2025-07-10 | Glenmark Life Sciences Limited | Process for the preparation of belumosudil mesylate and its crystalline form |
| WO2025069009A1 (en) * | 2023-09-29 | 2025-04-03 | Graviton Bioscience Bv | Rock2 inhibitors in the treatment of obesity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE346064T1 (de) * | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| PE20021011A1 (es) * | 2001-03-23 | 2003-02-01 | Bayer Corp | Derivados quinazolinicos como inhibidores de la rho-quinasa |
| ATE522207T1 (de) * | 2002-02-14 | 2011-09-15 | Kirin Brewery | Zusammensetzungen und nahrungsmittel zur verbesserung des fettstoffwechsels |
| CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| US20100168102A9 (en) * | 2005-07-11 | 2010-07-01 | Devgen Nv | Amide Derivatives as Kinase Inhibitors |
| DE602006018331D1 (de) * | 2005-09-20 | 2010-12-30 | Astrazeneca Ab | 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs |
| US20080021217A1 (en) * | 2006-07-20 | 2008-01-24 | Allen Borchardt | Heterocyclic inhibitors of rho kinase |
| CA2700988A1 (en) * | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
| WO2008077556A1 (en) * | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
-
2010
- 2010-03-09 AU AU2010222848A patent/AU2010222848A1/en not_active Abandoned
- 2010-03-09 EP EP10751284.0A patent/EP2406236A4/en not_active Withdrawn
- 2010-03-09 US US13/255,879 patent/US20120202793A1/en not_active Abandoned
- 2010-03-09 WO PCT/US2010/026656 patent/WO2010104851A1/en not_active Ceased
- 2010-03-09 MX MX2011009568A patent/MX2011009568A/es not_active Application Discontinuation
- 2010-03-09 JP JP2011554119A patent/JP2012519732A/ja active Pending
- 2010-03-09 CA CA2755095A patent/CA2755095A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012519732A (ja) | 2012-08-30 |
| EP2406236A4 (en) | 2013-07-24 |
| US20120202793A1 (en) | 2012-08-09 |
| EP2406236A1 (en) | 2012-01-18 |
| WO2010104851A1 (en) | 2010-09-16 |
| CA2755095A1 (en) | 2010-09-16 |
| AU2010222848A1 (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011009568A (es) | Inhibidores de la rho cinasa. | |
| WO2008054599A3 (en) | Rho kinase inhibitors | |
| SG179085A1 (en) | Pi3 kinase inhibitors and uses thereof | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| MX2010002783A (es) | Proceso e intermediarios para la preparacion de inhibidores de integrasa. | |
| ZA202000148B (en) | Heterocyclic inhibitors of atr kinase | |
| MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
| GEP20135849B (en) | Picolinamide derivatives as kinase inhibitors | |
| MX354402B (es) | Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos. | |
| WO2012158843A3 (en) | Kinase inhibitors | |
| MX2012013197A (es) | Inhibidores de indazol de cinasa. | |
| MX345552B (es) | Compuestos heterocíclicos útiles para inhibición de cinasa. | |
| EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
| MX2007011859A (es) | Compuestos mejorados farmacocineticamente. | |
| PH12015502091A1 (en) | Cdc7 inhibitors | |
| MX2010010209A (es) | 4-hidroxipirimidina-5-carboxamidas sustituidas. | |
| WO2010071846A3 (en) | Compounds for treating neuropsychiatric conditions | |
| HK1210615A1 (zh) | 胱硫醚-γ-裂合酶(CSE)抑制剂 | |
| AU2011278832A8 (en) | Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors | |
| ZA201102520B (en) | Pyridine and pyrimidine based compounds as wnt signaling pathway inhibitors for the treatment of cancer | |
| HK1210614A1 (en) | Cystathionine-υ-lyase (cse) inhibitors | |
| MX2012004780A (es) | Inhibidores de akt. | |
| EA201491647A1 (ru) | Основанные на арилэфирах ингибиторы киназ | |
| MX2015000980A (es) | Inhibidores de aril lactama cinasa. | |
| IN2014CN04050A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |